Updated results from MANIFEST arm 2: pelabresib as add-on to ruxolitinib in myelofibrosis

Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai, New York City, NY, gives an update on the MANIFEST study (NCT02158858) evaluating the efficacy and safety of pelabresib, an investigational BET inhibitor, as an add-on treatment to ruxolitinib in patients with myelofibrosis (MF) with a suboptimal response to ruxolitinib. The combination therapy showed promising results in terms of spleen and symptom responses. Additionally, a significant proportion of patients achieved transfusion independence. These findings suggest that pelabresib may hold potential as a treatment option for myelofibrosis patients who have an inadequate response to ruxolitinib monotherapy. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.